

PROGRAM: WEDNESDAY 7 OCTOBER

EPIDEMIOLOGY, SCREENING AND ASSESSMENT: ALL THESE FANCY DRUGS WON'T HAVE MUCH IMPACT IF WE DON'T GET PEOPLE ASSESSED!

7.30am	Registration
	Opening Ceremony and Session A: Epidemiology and transmission of HCV infection
8.00am - 10.30am	Room: The Grand Ballroom One Chair: Dr. Joseph Doyle, Burnet Institute, Australia and Eliot Ross Albers, International Network of People Who Use Drugs, United Kingdom
8.00am - 8.10am	Welcome To Country
8.10am - 8.20am	Introduction to the Conference Associate Professor Jason Grebely, UNSW, Australia
8.20am - 8.30am	Opening from Community Member Annie Madden, Australian Injecting and Illicit Drug Users League (AIVL), Australia
8.30am - 8.50am	Epidemiological definitions and estimates of populations of PWID with HCV infection Dr Sarah Larney, UNSW, Australia
8.50am - 9.10am	Emerging drug patterns and HCV transmission: An increasing cause for concern Professor Julie Bruneau, University of Montreal, Canada
9.10am - 9.30am	Molecular epidemiology of HCV among PWID: New insights into HCV transmission Professor Mel Krajden, British Columbia Centre for Disease Control and University of British Columbia, Canada
9.30am - 9.45am	Impact of Opiate Substitution Therapy and Needle Syringe Programmes on Incidence of HCV: A Systematic Review and Meta-Analysis Lucy Platt, London School of Hygiene and Tropical Medicine, United Kingdom
9.45am - 10.00am	Characterising Hepatitis C Virus Transmission Dynamics in a High-Risk Incarcerated Population Neil Bretana, UNSW, Australia
10.00am - 10.15am	Drawing Them In – Stories from People Who Know Heather McCormack, Hepatitis NSW, Australia
10.15am - 10.30am	HCV Treatment and Prevention: What is the Impact of Current and Scaled-Up Treatment Rates in Selected Sites in Europe? Hannah Woodall, University of Bristol, United Kingdom
10.30am - 11.00am	Morning Tea in Exhibition Hall
	Session B: Prevention and Treatment for HCV: From modelling to implementation
11.00am - 12.45pm	Room: The Grand Ballroom One Chair: Associate Prof Natasha Martin, University of California San Diego, United States and Annie Madden, Australian Injecting and Illicit Drug Users League (AIVL), Australia
11.00am- 11.15am	Strategies for the prevention of HCV infection Professor Lisa Maher, UNSW, Australia
11.15am- 11.30am	Prevention and Treatment for HCV: From modelling to implementation Professor Matthew Hickman, University of Bristol, United Kingdom
11.30am - 11.45am	HCV Treatment and Prevention in the Community - the Treatment and Prevention (TAP) study Professor Margaret Hellard, The Burnet Institute, Australia
11.45am - 12.00pm	HCV Treatment and Prevention in the Prison - the Surveillance and Treatment of Prisoners with hepatitis C (SToP-C) Study Professor Andrew Lloyd, UNSW, Australia
12.00pm - 12.15pm	The needs of PWID in the future of HCV care: Implications for treatment as prevention Dr. Magdalena Harris, London School of Hygiene and Tropical Medicine, United Kingdom
12.15pm - 12.45pm	Panel discussion

PROGRAM: WEDNESDAY 7 OCTOBER

EPIDEMIOLOGY, SCREENING AND ASSESSMENT: ALL THESE FANCY DRUGS WON'T HAVE MUCH IMPACT IF WE DON'T GET PEOPLE ASSESSED!			
12.45pm - 2.15pm		Lunch in Exhibition Hall	
12.45pm - 2.15pm		Satellite Symposium - Abbvie Room: The Grand Ballroom	
	Session C: Oral Abstracts HCV Epidemiology, Public Health and Modelling		Session D: Oral Abstracts Social and Community Research
2.15pm - 3.30pm	Room: The Grand Ballroom One Chair: Peter Vickerman, University of Bristol, United Kingdom and Mary Harrod, NSW Users and AIDS Association, Australia	2.15pm - 3.30pm	Room: The Grand Ballroom Two Chair: Magdalena Harris, London School of Hygiene and Tropical Medicine and Leona Quewezance, All Nations Hope Network, Canada
2.15pm - 2.30pm	Onward Transmission of Hepatitis C Virus Infection among Younger and Older People who Inject Drugs in Vancouver, Canada Brendan Jacka, UNSW, Australia	2.15pm - 2.30pm	The Next Step in Collaborative HCV Care - PWID, Partnerships and Potential to Treat Jenny Bourke, Hepatitis C Community Clinic and Charles Henderson, Needle Exchange Services Trust, New Zealand
2.30pm - 2.45pm	Network-Based Modeling for HCV in US Drug Injectors: Treatment as Prevention Alexei Zelenev, Yale School of Medicine, United States	2.30pm - 2.45pm	Experiences of PWID Community Network in Linking HCV Testing and Care to Treatment Using Direct Acting Antivirals Nalinikanta Rajkumar, Community Network for Empowerment (CoNE), India
2.45pm - 3.00pm	The Hepatitis C Epidemic Amongst Men who have Sex with Men: Modelling the Role of Behavioural Risk Heterogeneity and HIV Dependent Mixing Patterns Louis MacGregor, University of Bristol, United Kingdom	2.45pm - 3.00pm	Will the Moment of Hepatitis C Diagnosis Undermine the Promise of New Treatments? An Analysis of Canadian Women's Experiences Sandi Mitchell, University of Sydney, Canada
3.00pm - 3.15pm	Liver Disease Knowledge and Acceptability of Non-Invasive Liver Fibrosis Assessment among People who Inject Drugs in the Drug and Alcohol Setting: The Liverlife Study Alison Marshall, UNSW, Australia	3.00pm - 3.15pm	"It's Not Only My Life I Got to Worry About": Accounts of Needle-Syringe Sharing and Negotiated Safety among Couples who Inject Drugs Jake Rance, UNSW, Australia
3.15pm - 3.20pm	Female to Male Ratio of Hepatitis C Virus Incidence; A Systematic Review and Meta Analysis Aryan Esmaeili, Icahn School of Medicine at Mount Sinai, United States	3.15pm - 3.20pm	Hepatitis See - Low Literacy Hepatitis C Guide for People who Inject Drugs Clare Mannion, cohealth, Australia
3.20pm - 3.25pm	Relational and Contingent Risk and Harm Reduction: Blood-Borne Virus Prevention and Care in an Urban, Culturally Diverse Neighbourhood Elizabeth Peach, Burnet Institute, Australia	3.20pm - 3.25pm	Empowering Conscious Health Consumers in a Changing Treatment Landscape Kyle Leadbeatter, Hepatitis NSW, Australia
3.25pm - 3.30pm	HCV Diagnostic Screening among People who Inject Drugs in Australia Jenny Iversen, UNSW, Australia	3.25pm - 3.30pm	Making Hepatitis C Treatment a National Priority in Georgia through Drug Users Community Advocacy Paata Sabelashvili, Georgian Harm Reduction Network, Georgia
3.30pm - 4.00pm		Afternoon Tea in Exhibition Hall	

EPIDEMIOLOGY, SCREENING AND ASSESSMENT: ALL THESE FANCY DRUGS WON'T HAVE MUCH IMPACT IF WE DON'T GET PEOPLE ASSESSED!

Session E: Enhancing Access to Screening and Assessment for HCV infection

4.00pm - 5.40pm	Room: The Grand Ballroom One Chair: Dr. Jenny Iversen, The Kirby Institute, UNSW, Australia and Kim Gates, Northern Territory AIDS and Hepatitis Council, Australia
4.00pm - 4.20pm	Barriers to HCV screening, diagnosis and assessment: A community perspective Jude Byrne, Australian Injecting and Illicit Drug Users League, Australia
4.20pm - 4.40pm	Barriers to access to screening and assessment of HCV from a patient perspective: A review of the qualitative literature Professor Carla Treloar, UNSW, Australia
4.40pm - 5.00pm	Interventions to enhance testing and diagnosis of HCV infection among PWID Professor David Goldberg, Glasgow Caledonian University, Scotland
5.00pm - 5.20pm	Diagnosis and treatment of acute HCV infection in the IFN-free era: Does it really matter? Associate Professor Gail Matthews, UNSW, Australia
5.20pm - 5.40pm	Non-invasive liver fibrosis assessment: Opportunities for enhanced liver disease assessment and treatment in the drug and alcohol setting Professor Alessio Aghemo, University of Milan, Italy
5.40pm	End of Conference Day One
6.00pm - 7.00pm	Drink Reception - Beachside DOJO

PROGRAM: THURSDAY 8 OCTOBER

TREATMENT AND CARE: BUILDING THE EVIDENCE FOR EXPANDING HCV TREATMENT AMONG PWID	
8.00am	Registration
Session F: Treatment of Viral Hepatitis	
8.30am - 10.45am	Room: The Grand Ballroom One Chair: Professor Olav Dalgard, Akershus University Hospital, Norway and Tracy Swan, Treatment Action Group, United States
8.30am - 9.00am	IFN-free therapy for HCV infection: In search of perfectovir Associate Professor Jordan Feld, University of Toronto, Canada
9.00am - 9.20am	Interventions to enhance treatment and adherence to IFN-free HCV therapy among PWID Professor Alain Litwin, Albert Einstein College of Medicine, United States
9.20am - 9.40am	Models of care for management of HCV among PWID Dr. Philip Bruggman, Arud Centres for Addiction Medicine, Switzerland
9.40am - 9.55am	C-EDGE CO-STAR: Adherence and Drug use in HCV-Infected Persons who Inject Drugs (PWID) on Opioid Agonist Therapy (OAT) receiving Grazoprevir + Elbasvir (GZR/EBR) fixed Dose Combination (FDC) for 12 Weeks Greg Dore, UNSW, Australia
9.55am - 10.10am	High Rates of Sustained Virological Response in People Who Inject Drugs Treated with Sofosbuvir-Based Regimens Alain Litwin, Albert Einstein College of Medicine and Montefiore Medical Center, United States
10.10am - 10.25am	Evaluation of two community-controlled peer support services for assessment and treatment of hepatitis C virus infection in opioid substitution treatment clinics: The ETHOS Study, Australia Carla Treloar, UNSW, Australia
10.25am - 10.40am	Hepatitis C Reinfection Following Sustained Virological Response - A Seven Year Follow-Up of Norwegian Patients Infected through Injecting Drug Use Håvard Midgard, Akershus University Hospital, Norway
10.40am - 10.45am	Expanding access to prevention, care and treatment for hepatitis C virus infection among people who inject drugs: Special Issues from the International Journal of Drug Policy Professor Gerry Stimson, London School of Hygiene and Tropical Medicine and Editor, International Journal of Drug Policy, United Kingdom
10.45am - 11.15am	Morning Tea in Exhibition Hall
Session G: Debate	
11.15am - 12.15pm	Room: The Grand Ballroom One Hepatitis C treatment prioritization is needed in the current setting of high drug pricing PRO: Matthew Hickman (UK), Margaret Hellard (Australia) and Karyn Kaplan (United States) CON: Marina Klein (Canada), Andrew Hill (UK) and Annie Madden (Australia) Moderator: Carla Treloar (Australia)
12.15pm - 1.45pm	Lunch in Exhibition Hall
12.15pm - 1.45pm	Satellite Symposium - Gilead Room: The Grand Ballroom

TREATMENT AND CARE: BUILDING THE EVIDENCE FOR EXPANDING HCV TREATMENT AMONG PWID

	Session H: Oral Abstracts HCV treatment and management		Session I: Oral Abstracts HCV Epidemiology and Screening
1.45pm - 3.00pm	Room: The Grand Ballroom One Chair: Dr. John Dillon, University of Dundee, United Kingdom and Fiona Poeder, NSW Users and AIDS Association, Australia	1.45pm - 3.00pm	Room: The Grand Ballroom Two Chair: Professor Gerry Stimson, London School of Hygiene and Tropical Medicine and Charles Henderson, New Zealand Needle Exchange Programme
1.45pm - 2.00pm	Efficacy of Response-Guided Pegylated Interferon & Ribavirin Therapy for People who Inject Drugs with HCV Genotype 2/3 Infection: The ACTIVATE Study Jason Grebely, UNSW, Australia	1.45pm - 2.00pm	Hepatitis C Treatment Uptake among Patients Receiving Opioid Substitution Treatment: A Population Based Study Håvard Midgard, Akershus University Hospital, Norway
2.00pm - 2.15pm	Evaluation of Treatment of HCV Infection in Active Injection Drug Users Arshia Alimohammadi, Vancouver Infectious Diseases Centre, Canada	2.00pm - 2.15pm	Changes in Injection Drug Use among Recently Hepatitis C Virus-Infected Persons who Inject Drugs Offered Treatment in Montreal, Canada Andreea Adelina Artenie, Université de Montréal, Canada
2.15pm - 2.30pm	How should HCV Antiviral Treatment be Prioritized in the Direct-Acting Antiviral Era? An Economic Evaluation including Individual and Population Prevention Benefits Natasha Martin, University of California San Diego, United States	2.15pm - 2.30pm	The Potential Prevention Impact of Scaling Up Hepatitis C Virus Treatment for People who Inject Drugs in Prison: A Modeling Analysis for Scotland Jack Stone, University of Bristol, United Kingdom
2.30pm - 2.45pm	Hepatitis C Treatment for People who Inject Drugs: Are Direct-Acting Antivirals Cost-Effective? Daniela Van Santen, Public Health Service of Amsterdam, Netherlands	2.30pm - 2.45pm	Modelling the Impact of a National Scale Up of Interventions on Hepatitis C Virus Transmission among People who Inject Drugs in Scotland Hannah Woodall, University of Bristol, United Kingdom
2.45pm - 2.50pm	Pilot Study: Combining Formal and Peer Education with Fibroscan to Increase HCV Screening and Treatment in Persons Who Inject Drugs Amber Arain, Hasselt University, Belgium	2.45pm - 2.50pm	Factors Associated with Undiagnosed Hepatitis C Infection among People who Inject Drugs: Missed Opportunities for Diagnostic Testing in The United Kingdom (UK) Vivian Hope, Public Health England, United Kingdom
2.50pm - 2.55pm	A Single Tablet Regimen of Ledipasvir + Sofosbuvir is Efficacious and Well-Tolerated Among People Receiving Opiate Substitution Therapy Jason Grebely, UNSW, Australia	2.50pm - 2.55pm	Trends in End-Stage Liver Disease among People Receiving Opioid Substitution Therapy with an HCV Notification in New South Wales, Australia between 1993 and 2012 Reem Waziry, UNSW, Australia
2.55pm - 3.00pm	Is Increased HCV Case-Finding Combined With 8-12 Week Interferon-Free Direct-Acting Antiviral Treatment Cost-Effective in UK Prisons? A Dynamic Cost Utility Analysis including Treatment as Prevention Benefits Natasha Martin, University of California San Diego, United States	2.55pm - 3.00pm	The Community Pop-Up Clinic as a Tool of Engagement for Vulnerable Populations with HCV and HIV Infection Syune Hakobyan, Vancouver ID Research and Care Centre Society, Canada
3.00pm - 3.30pm	Afternoon Tea in Exhibition Hall		

PROGRAM: THURSDAY 8 OCTOBER

TREATMENT AND CARE: BUILDING THE EVIDENCE FOR EXPANDING HCV TREATMENT AMONG PWID

Session J: Important issues for the management HCV among PWID

3.30pm
- 5.10pm

Room: The Grand Ballroom One
Chair: Prof. Geert Robaey, Ziekenhuis Oost Limburg, Belgium and Mohamad Firdaus, Malaysian WARDU, Malaysia

3.30pm
- 3.40pm

The Change Project: International stories of PWID with HCV who have received interferon-free treatment

3.40pm
- 4.00pm

A national multidisciplinary healthcare network for treatment of hepatitis C in PWID in Slovenia
Professor Mojca Maticic, University Medical Centre, Ljubljana, Slovenia

4.00pm
- 4.20pm

Peer support for HCV infection: The potential for transformation in the drug and alcohol setting
Sione Crawford, Canberra Alliance for Harm Minimisation and Advocacy, Australia

4.20pm
- 4.40pm

The Hep C European Initiative: Integrating research, practice and policy
Eberhard Schatz, Correlation Network, Amsterdam, The Netherlands

4.40pm
- 5.00pm

Epidemiology of HCV reinfection and mixed infection in the treatment setting
Dr. Janke Schinkel, Academic Medical Center of the University of Amsterdam, The Netherlands

5.00pm
- 5.20pm

Management of HCV/HIV co-infection in the IFN-free era
Professor Marina Klein, McGill University Health Centre, Canada

5.20pm

End of Conference Day Two

7.00pm
- 11.00pm

Conference Dinner - Taronga Zoo

PROGRAM: FRIDAY 9 OCTOBER

ACCESS AND IMPLEMENTATION: MOVING FORWARD TOWARDS EQUITABLE ACCESS TO HCV CARE FOR PWID	
8.00am	Registration
Session K: HCV Diagnostics and Therapeutics: Where are we now and where are we going	
8.30am - 10.30am	Room: The Grand Ballroom One Chair: Dr. Philip Bruggman, Arud Centres for Addiction Medicine, Switzerland and Paata Sabelashvili, Georgian Harm Reduction Network, Georgia
8.30am - 9.00am	Will HCV therapies deliver global impact? Professor Greg Dore, UNSW, Australia
9.00am - 9.20am	HCV diagnostics and non-invasive liver disease assessments: What are the current tools in the toolbox and where to from here? Professor Karine Lacombe, Hospital Saint-Antoine, Paris, France
9.20am - 9.40am	Strategies for rolling out testing and treatment for PWID: Evidence from the Ukraine Ludmila Maistat, International HIV/AIDS Alliance, Ukraine
9.40am - 10.00am	Strategies for rolling out harm reduction, and HCV and HBV testing among PWID: Evidence from East Africa Dr. Zin Mar Han, Medecins du Monde-France, Kenya
10.00am - 10.30am	Morning Tea in Exhibition Hall
Session L: Access and implementation for all: Prevention, care and treatment	
10.30am - 1.00pm	Room: The Grand Ballroom One Chair: Professor Matthew Hickman, University of Bristol, United Kingdom and Nalinikanta Rajkumar, Community Network for Empowerment (CoNE), India
10.30am - 10.50am	Access and implementation of IFN-free therapy: where to from here for low and middle income countries Niklas Luhman, Medecins du Monde, France
10.50am - 11.10am	What is the minimum cost to cure Hepatitis C? Dr. Andrew Hill, Liverpool University, United Kingdom
11.10am - 11.30am	Efforts from the community to improve access Karyn Kaplan, Director, Treatment Action Group, United States
11.30am - 11.40am	The Change Project: Challenges and strategies to enhance HCV testing, linkage to care and HCV treatment among PWID
11.40pm - 1.00pm	Panel Discussion: Challenges and strategies successful for enhancing HCV testing and care among PWID Chair: Professor Margaret Hellard, the Burnet Institute, Australia
1.00pm - 2.30pm	Lunch in Exhibition Hall
1.00pm - 2.30pm	Satellite Symposium - MSD Room: The Grand Ballroom

PROGRAM: FRIDAY 9 OCTOBER

ACCESS AND IMPLEMENTATION: MOVING FORWARD TOWARDS EQUITABLE ACCESS TO HCV CARE FOR PWID

Session M: The HCV care package: What should it include and how can we deliver it?

2.30pm
- 5.00pm

Room: The Grand Ballroom One
Chair: Nicky Bath, NSW Ministry of Health, Australia
and Fifa Rahman, Malaysian AIDS Council, Malaysia

2.30pm
- 2.50pm

Integrating HCV prevention, care and treatment for PWID: A community perspective
Eliot Ross Albers, International Network of People Who Use Drugs, United Kingdom

2.50pm
- 3.10pm

Human rights and structural barriers to treatment access
Daniel Wolfe, Open Society Foundation, United States

3.10pm
- 3.30pm

WHO guidelines on HCV screening, treatment and care: relevance for PWID
Professor Margaret Hellard, The Burnet Institute, Australia

Session N: Rapporteur Sessions and Conference Closing

3.30pm
- 3.45pm

Report from Community and Advocacy Workshop
Stione Crawford, Canberra Alliance for Harm Minimisation and Advocacy, Australia

3.45pm
- 4.30pm

Rapporteur report
Associate Professor Jason Grebely, UNSW Australia, Tracy Swan, Treatment Action Group,
United States, Associate Professor Jordan Feld, University of Toronto, Canada

4.30pm
- 4.45pm

Community Closing Statement
Charles Henderson, New Zealand Needle Exchange Programme, New Zealand

4.45pm
- 5.00pm

Conference closing
Professor Greg Dore, UNSW, Australia

5.00pm

End of Conference